Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,581.00
(
1.15%
)
US TECH 100
23,533.60
(
1.08%
)
Dow Jones
46,208.47
(
1.38%
)
Brent Oil
97.46
(
-9.87%
)
Bitcoin
70,887.53
(
4.50%
)
News Focus
News Focus
Post# of 257272
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122807
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 205572

Monday, 10/31/2016 3:57:45 PM

Monday, October 31, 2016 3:57:45 PM

Post# of 257272
ZBH addendum and a question:

ZBH’s 3Q16 worldwide YoY product pricing was -1.8%, which is close to what it has been for many consecutive quarters.

Yet despite today’s sell-off, ZBH (the stock) has had a fabulous run during the past few years.

So, why is a market environment with flat to slightly negative pricing ok for a medical-device company, but (supposedly) not ok for a drug/biotech company?

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today